Personalized medicine for gliomas

Surgical Neurology International

Volumn 6, Issue 2, 2015, Pages S89-S95

  Ene, Chibawanye ^a   Holland, Eric ^a,b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Glioblastoma multiforme; Glioma; Personalized medicine; Targeted therapy; Tumor heterogeneity; Tumor vaccines

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; IMATINIB; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PEPTIDE VACCINE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR A INHIBITOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VEMURAFENIB;

ADJUVANT CHEMORADIOTHERAPY; ANTIGEN EXPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL HETEROGENEITY; CLINICAL DECISION MAKING; CONTROLLED CLINICAL TRIAL (TOPIC); GENE MUTATION; GENETIC VARIABILITY; GLIOBLASTOMA; HUMAN; IMMUNOSURVEILLANCE; INTER TUMORAL HETEROGENEITY; INTRA TUMORAL HETEROGENEITY; MACROPHAGE MIGRATION INHIBITION; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN METHYLATION; PROTEIN TARGETING; REVIEW; SURVIVAL TIME; TUMOR CELL; TUMOR CLASSIFICATION; TUMOR IMMUNOLOGY;

EID: 84929873842     PISSN: None     EISSN: 21527806     Source Type: Journal    
DOI: 10.4103/2152-7806.151351     Document Type: Review

References (36)

1. Ardon H, Van Gool S, Lopes IS, Maes W, Sciot R, Wilms G, et al. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: A pilot study. J Neurooncol 2010;99:261-72.
2. Bhat K P, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, et al. Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell 2013;24:331-46.
3. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
4. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155:462-77.
5. Chaumeil MM, Larson PE, Yoshihara HA, Danforth OM, Vigneron DB, Nelson SJ, et al. Non-invasive in vivo assessment of IDH1 mutational status in glioma. Nat Commun 2013;4:2429.
6. Cheng W Y, Kandel JJ, Yamashiro DJ, Canoll P, Anastassiou D. A multi-cancer mesenchymal transition gene expression signature is associated with prolonged time to recurrence in glioblastoma. PloS One 2012;7:e34705.
7. Choi BD, Archer GE, Mitchell DA, Heimberger AB, McLendon RE, Bigner DD, et al. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol 2009;19:713-23.
8. Elkhaled A, Jalbert LE, Phillips JJ, Yoshihara HA, Parvataneni R, Srinivasan R, et al. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci Transl Med 2012;4:116ra5.
9. Ene CI, Fine HA. Many tumors in one: A daunting therapeutic prospect. Cancer Cell 2011;20:695-7.
10. Fadul CE, Fisher JL, Hampton TH, Lallana EC, Li Z, Gui J, et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother 2011;34:382-9.
11. Greenberg MS. Handbook of Neurosurgery, 7th ed. Greenberg MS: Thieme Medical Publishers; 2006.
12. Hegi ME, Diserens AC, Gorlia T, Hamou M F, de Tribolet N, Weller M, et al. MGMT gene silencing and beneft from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
13. Huse J T, Holland E, DeAngelis LM. Glioblastoma: Molecular analysis and clinical implications. Annu Rev Med 2013;64:59-70.
14. Katz AM, Amankulor NM, Pitter K, Helmy K, Squatrito M, Holland EC. Astrocyte-specifc expression patterns associated with the PDGF-induced glioma microenvironment. PloS One 2012;7:e32453.
15. Kleihues P, Burger PC, Scheithauer BW. The new WHO classifcation of brain tumours. Brain Pathol 1993;3:255-68.
16. Liu C, Sage JC, Miller MR, Verhaak RG, Hippenmeyer S, Vogel H, et al. Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell 2011;146:209-21.
17. Mukherjee S. The Emperor of All Maladies: Scribner, 2011.
18. Naeini KM, Pope WB, Cloughesy T F, Harris RJ, Lai A, Eskin A, et al. Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. Neuro Oncol 2013;15:626-34.
19. Navin N, Hicks J. Future medical applications of single-cell sequencing in cancer. Genome Med 2011;3:31.
20. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. Nature 2011;472:90-4.
21. Navin N, Krasnitz A, Rodgers L, Cook K, Meth J, Kendall J, et al. Inferring tumor progression from genomic heterogeneity. Genome Res 2010;20:68-80.
22. Navin NE, Hicks J. Tracing the tumor lineage. Mol Oncol 2010;4:267-83.
23. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al., Cancer Genome Atlas Research N. Identifcation of a CpG island methylator phenotype that defnes a distinct subgroup of glioma. Cancer Cell 2010;17:510-22.
24. Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuno MA, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 2013;62:125-35.
25. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 2013;19:1264-72.
26. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med 2012;366:2517-9.
27. Shiow LR, Roadcap DW, Paris K, Watson SR, Grigorova IL, Lebet T, et al. The actin regulator coronin 1A is mutant in a thymic egress-defcient mouse strain and in a patient with severe combined immunodefciency. Nat Immunol 2008;9:1307-15.
28. Siolas D, Hannon GJ. Patient-derived tumor xenografts: Transforming clinical samples into mouse models. Cancer Res 2013;73:5315-9.
29. Snuderl M, Fazlollahi L, Le L P, Nitta M, Zhelyazkova BH, Davidson CJ, et al. Mosaic amplifcation of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011;20:810-7.
30. Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y, et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplifcation in glioblastoma defnes subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A 2012;109:3041-6.
31. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defnes human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
32. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
33. Van Gool S, Maes W, Ardon H, Verschuere T, Van Cauter S, De Vleeschouwer S. Dendritic cell therapy of high-grade gliomas. Brain Pathol 2009;19:694-712.
34. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
35. Wang X, Chen JX, Liu YH, You C, Mao Q. Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O (6)-methylguanine DNA-methyltransferase. Neurol Sci 2013;34:1421-8.
36. Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 2013;81:1515-22.